7 Best Alternatives to GRAIL for Cancer Detection in 2026

Why look beyond GRAIL

GRAIL's Galleri multi-cancer early detection test is designed to identify a signal shared by multiple cancers and localize the cancer signal origin in asymptomatic individuals when used as an adjunct to standard screenings [source]. While this represents a significant advancement in early detection, healthcare professionals may seek alternatives due to several factors. These can include a desire for tests focusing on specific cancer types, different biomarker technologies, or a broader spectrum of diagnostic and prognostic capabilities. Some alternatives offer established screening programs for specific cancers, while others employ distinct liquid biopsy approaches that might complement or extend the insights provided by Galleri. Evaluating the landscape of early cancer detection technologies allows clinicians to tailor testing strategies to individual patient profiles and clinical needs.

Top alternatives ranked

1. 1. Exact Sciences — Established leader in cancer screening and diagnostics

   Exact Sciences provides a range of cancer screening and diagnostic tests, notably Cologuard for colorectal cancer screening. Their portfolio also includes Oncotype DX for breast, colon, and prostate cancer recurrence risk assessment, and various precision oncology tests [source]. Unlike GRAIL's multi-cancer early detection approach, Exact Sciences focuses on specific cancer types with well-established screening protocols and diagnostic applications. This makes them a strong alternative for clinicians prioritizing validated, single-cancer specific screening programs and comprehensive diagnostic insights.

   • Best for: Established, single-cancer screening programs (e.g., colorectal cancer), comprehensive diagnostic and prognostic guidance for specific cancers.
   • Exact Sciences profile page

2. 2. Guardant Health — Liquid biopsy for advanced cancer management

   Guardant Health specializes in liquid biopsy tests for advanced cancer patients, offering solutions like Guardant360 for comprehensive genomic profiling and Guardant Reveal for molecular residual disease (MRD) detection [source]. Their focus is primarily on guiding treatment decisions and monitoring recurrence in patients already diagnosed with cancer, rather than multi-cancer early detection in asymptomatic individuals. However, Guardant Health is also developing early detection tests, such as Shield, which aims to screen for colorectal cancer. For oncologists managing advanced cancer or monitoring for recurrence, Guardant Health's precise liquid biopsy solutions offer a distinct and complementary approach to GRAIL's offering.

   • Best for: Genomic profiling in advanced cancer, molecular residual disease detection, guiding treatment decisions, and monitoring recurrence.
   • Guardant Health profile page

3. 3. Freenome — Multi-omics for early cancer detection

   Freenome is developing multi-omics platforms for early cancer detection and precision oncology, with an initial focus on colorectal cancer screening [source]. Their approach combines cell-free DNA (cfDNA) with protein biomarkers and machine learning to detect cancer signals. Similar to GRAIL, Freenome aims to detect cancer at its earliest stages, but their multi-omics strategy offers a different technological approach to biomarker discovery and validation. For healthcare providers interested in innovative, multi-biomarker approaches to early detection, Freenome represents a close conceptual alternative with a distinct scientific foundation.

   • Best for: Multi-omics approach to early cancer detection, advanced biomarker discovery, colorectal cancer screening with a focus on comprehensive biological signals.
   • Freenome profile page

4. 4. Google Health AI — Research and development in AI for healthcare

   Google Health AI is involved in broad research and development efforts to apply artificial intelligence across various healthcare domains, including medical imaging, genomics, and disease detection [source]. While not a direct provider of clinical tests like GRAIL, Google Health AI's initiatives contribute foundational AI technologies that could underpin future early detection solutions. Their work includes projects on retinal imaging for disease prediction and AI models for pathology. For organizations or researchers interested in partnering on the development of next-generation AI-powered diagnostics or leveraging advanced AI models in their own healthcare applications, Google Health AI represents a significant player in the underlying technological advancements.

   • Best for: Research collaborations in AI for healthcare, leveraging advanced AI models for medical imaging and diagnostics, developing new AI-powered disease detection methods.
   • Google AI profile page

5. 5. Microsoft Health AI — AI solutions for healthcare infrastructure and research

   Microsoft offers various AI services and platforms through Azure AI, which are utilized in healthcare for data analysis, clinical decision support, and medical imaging [source]. While Microsoft does not directly provide a multi-cancer early detection test akin to GRAIL's Galleri, their cloud infrastructure and AI tools enable healthcare organizations to develop and deploy their own AI-driven solutions. This includes leveraging machine learning for biomarker discovery, predictive analytics for patient risk stratification, and natural language processing for clinical data. For healthcare systems and biotech companies looking to build custom AI solutions for diagnostics or research, Microsoft's robust AI ecosystem offers a powerful alternative to develop internal capabilities.

   • Best for: Developing custom AI-driven diagnostic tools, leveraging cloud-based AI infrastructure for healthcare research, building predictive analytics models for patient care.
   • Azure OpenAI Service profile page

6. 6. DeepMind — Advancing AI for scientific discovery and healthcare challenges

   DeepMind, an AI research laboratory, focuses on developing advanced artificial intelligence to solve complex scientific problems, including those in healthcare [source]. Their work on AlphaFold, which predicts protein structures, has significant implications for drug discovery and understanding disease mechanisms. While DeepMind does not offer direct diagnostic tests, their foundational AI research in areas like protein folding, medical imaging analysis, and genomics contributes to the scientific bedrock upon which future early detection technologies, including those for cancer, can be built. For researchers and organizations at the forefront of AI-driven scientific discovery in health, DeepMind's contributions are highly relevant.

   • Best for: Foundational AI research for scientific discovery, protein structure prediction, advancing AI for complex biological and medical challenges, understanding disease mechanisms at a molecular level.
   • DeepMind profile page

7. 7. AWS SageMaker — Machine learning platform for healthcare and life sciences

   AWS SageMaker provides an end-to-end platform for building, training, and deploying machine learning models, offering specific services and solutions tailored for healthcare and life sciences [source]. While not a direct competitor to GRAIL's clinical test, SageMaker enables organizations to develop their own AI models for tasks such as biomarker discovery, image analysis for diagnostics, and predictive analytics for patient outcomes. This platform supports the entire machine learning lifecycle, from data labeling to model deployment, and integrates with other AWS services for secure data storage and processing. For healthcare providers and biotech companies with data science teams looking to develop custom AI solutions for early detection or other clinical applications, SageMaker offers a scalable and comprehensive development environment.

   • Best for: Building and deploying custom machine learning models for healthcare, biomarker discovery and validation, medical image analysis, predictive analytics in clinical research.
   • AWS SageMaker profile page

Side-by-side

How to pick

Selecting an alternative to GRAIL's Galleri test depends on the specific clinical objectives, the target patient population, and the desired technological approach for cancer detection and management. Consider the following decision points:

• For established, single-cancer screening: If the primary need is for well-validated screening tests for specific cancers with clear clinical guidelines, Exact Sciences offers established solutions like Cologuard for colorectal cancer [source]. These options are often integrated into routine clinical practice.
• For advanced cancer management and liquid biopsy: When the focus is on genomic profiling for treatment selection, monitoring therapy response, or detecting molecular residual disease in diagnosed cancer patients, Guardant Health provides specialized liquid biopsy platforms [source]. Their offerings are geared towards precision oncology.
• For innovative multi-omics early detection: If exploring cutting-edge approaches to early cancer detection that combine multiple biomarker types (e.g., cfDNA and proteins) with machine learning, Freenome is developing a multi-omics platform with similar goals to GRAIL but a distinct technological strategy [source].
• For leveraging general-purpose AI in healthcare: For organizations seeking to build internal capabilities for AI-driven diagnostics, biomarker discovery, or clinical decision support, consider cloud-based AI platforms. Microsoft Health AI (via Azure AI) and AWS SageMaker provide the infrastructure and tools to develop custom machine learning solutions for various healthcare applications [source] [source]. These are platforms for development rather than off-the-shelf clinical tests.
• For academic or research collaborations: If the interest lies in foundational AI research that could impact future diagnostic methods, partnerships or engagement with organizations like Google Health AI or DeepMind are relevant. Their work contributes to the underlying scientific and technological advancements in AI for health, though they do not offer direct clinical tests [source] [source].